骨髓增生异常综合征中JAK2 V617F突变克隆的出现与疾病进展及骨髓纤维化特征相关。 - Suppr | 超能文献

The emergence of a JAK2 V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis.

作者信息

Zhong Boris, Medeiros L Jeffrey, Wang Wei

机构信息

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Br J Haematol. 2019 Aug;186(3):396. doi: 10.1111/bjh.15984. Epub 2019 May 28.

DOI:10.1111/bjh.15984

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The emergence of a JAK2 V617F-mutated clone in myelodysplastic syndrome is associated with disease progression and features of myelofibrosis.骨髓增生异常综合征中JAK2 V617F突变克隆的出现与疾病进展及骨髓纤维化特征相关。

Br J Haematol. 2019 Aug;186(3):396. doi: 10.1111/bjh.15984. Epub 2019 May 28.

2

The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.JAK2 V617F突变在骨髓增生异常/骨髓增殖性疾病中频繁出现，但在伴有纤维化的真性骨髓增生异常综合征中不存在。

Leukemia. 2006 Jul;20(7):1315-6. doi: 10.1038/sj.leu.2404231. Epub 2006 Apr 13.

3

Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.对克雷默·M等人的回复：JAK2 V617F突变在骨髓增生异常/骨髓增殖性疾病中频繁出现，但在伴有纤维化的真性骨髓增生异常综合征中不存在。

Leukemia. 2006 Jul;20(7):1297-8. doi: 10.1038/sj.leu.2404232. Epub 2006 Apr 13.

4

Comparison of JAK2 -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.JAK2 阳性原发性血小板增多症与早期原发性骨髓纤维化的比较：突变负荷和组织学的影响

Hematol Oncol. 2018 Feb;36(1):269-275. doi: 10.1002/hon.2430. Epub 2017 May 16.

5

The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.JAK2 V617F突变与伴有或不伴有骨髓纤维化的骨髓增生异常综合征之间缺乏关联。

Leukemia. 2006 Jun;20(6):1165. doi: 10.1038/sj.leu.2404196.

6

The disappearance of two alleles of JAK2 V617F from peripheral blood of a polycythaemia vera patient correlates with transformation into myelofibrosis.真性红细胞增多症患者外周血中JAK2 V617F两个等位基因的消失与向骨髓纤维化转化相关。

Br J Haematol. 2007 Sep;138(6):822-3. doi: 10.1111/j.1365-2141.2007.06743.x.

7

The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients.骨髓增生异常综合征（MDS）发展为骨髓纤维化时出现的JAK2 V617F酪氨酸激酶突变表明一部分MDS患者具有骨髓增殖性特征。

Leukemia. 2005 Dec;19(12):2359-60. doi: 10.1038/sj.leu.2403989.

8

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.一种由年龄、JAK2、CALR和MPL突变状态组成的用于原发性骨髓纤维化患者的准确、简单的预后模型。

Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.

9

Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.伴有JAK2 V617F的原发性血小板增多症中反复出现的der(9;18)与骨髓纤维化的发展高度相关。

Cancer Genet Cytogenet. 2008 Oct;186(1):6-11. doi: 10.1016/j.cancergencyto.2008.04.021.

10

Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.伴有纤维化的慢性髓单核细胞白血病是一种具有骨髓增殖性特征且常伴有 JAK2 p.V617F 突变的独特疾病亚型。

Am J Surg Pathol. 2018 Jun;42(6):799-806. doi: 10.1097/PAS.0000000000001058.

引用本文的文献

1

Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.骨髓增生异常综合征和骨髓增生异常/骨髓增殖性肿瘤的进展、转化和不典型表现：从 2019 年第十四届欧洲骨髓工作小组课程中获得的经验教训。

Ann Hematol. 2021 Jan;100(1):117-133. doi: 10.1007/s00277-020-04307-9. Epub 2020 Oct 31.